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Abstract 42 
Objectives 43 
To reduce the risk of symptomatic lymphocele after robotic pelvic lymph node dissection 44 
(PLND), we present a novel technique (P.L.E.A.T.): the peritoneum is ‘pleated’ along its 45 
midline, leaving two lateral openings and allowing lymphatic fluid to drain away from the 46 
pelvis and into the abdomen. 47 
Methods 48 
We analysed a single-surgeon series of PLNDs during Robotic Radical Prostatectomy, 49 
comparing 195 ‘standard’ PLNDs (in which the peritoneum was ‘re-approximated’ or left 50 
completely open) with 176 cases in which P.L.E.A.T. was performed.  51 
Results 52 
In the group without P.L.E.A.T., 8 cases of symptomatic (Grade ≥3, according to the 53 
Clavien Dindo Classification) lymphoceles (4.1%) were recorded. Only one P.L.E.A.T. 54 
patient complained of symptoms due to a lymphocele (p=0.039). No patient reported 55 
complications due to the procedure. 56 
Conclusions 57 
The P.L.E.A.T. technique is a fast, easy-to-perform and safe method of reducing the risk of 58 
symptomatic lymphocele after transperitoneal robotic PLND. 59 
 60 
Page 2 of 14
3 
 61 
Introduction 62 
 63 
The formation of a pelvic lymphocele is a complication which may follow robotic pelvic 64 
lymph node dissection (PLND). Most cases of lymphocele are asymptomatic (incidence 65 
reaches 30%) and are often an incidental finding during follow-up1,2. When symptoms do 66 
occur (incidence after robotic PLND 0-8% - Grade ≥3, according to the Clavien Dindo 67 
Classification3), they are typically related to compression of surrounding structures (pelvic 68 
pain, leg edema, deep vein thrombosis)4.  69 
 70 
An injury to the lymphatic vessels is the main causative factor in the formation of a 71 
lymphocele. Potential risk factors for its development are: surgical approach (laparotomy 72 
vs. laparoscopy/robotic), number of lymph nodes removed, lymph node status, and type of 73 
cancer. 74 
 75 
Several studies have shown a lower incidence of lymphocele after robotic radical 76 
prostatectomy (RARP) with PLND, by means of a transperitoneal approach rather than 77 
traditional open or extraperitoneal approaches. Initial peritoneotomy is probably the main 78 
reason for the decreased incidence of lymphocele formation during transperitoneal PLND. 79 
The opening created during this approach allows lymphatic fluid to drain away from the 80 
pelvis and into the abdomen. Nevertheless, the incidence of lymphocele is also higher 81 
than anticipated, in view of the believed protective effect of the transperitoneal approach5,6. 82 
 83 
The aim of this study was to analyse the incidence to date of symptomatic lymphocele and 84 
to assess the protective role of a novel surgical technique to prevent its formation in a 85 
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large cohort of patients followed after robotic PLND and transperitoneal RARP for prostate 86 
cancer. 87 
Materials and Methods 88 
We analysed a single-surgeon (FDM) series of PLNDs during RARP, comparing 195 89 
‘standard’ PLNDs (in which the peritoneum was ‘re-approximated’ or left completely open) 90 
with 176 cases, in which a ‘partial’ closure of the peritoneum was performed.  91 
The aim of this novel technique, named P.L.E.A.T. (acronym: Preventing Lymphocele 92 
Ensuring Absorption Transperitoneally) is to create a pathway lined by peritoneum, to 93 
direct lymphatic fluid out of the pelvis and into the peritoneal cavity where it can be 94 
absorbed: the peritoneum is ‘pleated’ along its midline and fixed to the fibers of the rectus 95 
abdominis muscles, near the pubis. The P.L.E.A.T. technique, leaving two lateral 96 
openings, allows lymphatic fluid to drain away from the pelvis and into the abdomen 97 
[Figure #1]. 98 
 99 
We excluded the first 50 cases of PLND performed by the surgeon FDM from this series: 100 
in these cases we found 4 symptomatic lymphoceles, but because the cooperation with 101 
other surgeons and a non-standardized technique, we decided to exclude the above cases 102 
in order to avoid any bias due to the initial learning curve. Although including the first 50 103 
cases would have allowed us to increase the level of significance of this study (p value 104 
from 0.038 to 0.01), it would not have been methodologically correct. 105 
All patients were managed similarly in the perioperative period (i.e. same timing for 106 
catheter/pelvic drain removal). In view of Deep Vein Thrombosis (DVP) prophylaxis, we 107 
treated all patients with subcutaneous low molecular weight heparin (Enoxaparin) at a 108 
dosage of 3000 UI/day (modified according to specific risk, renal function, body mass 109 
index) and graduated compression stockings. We usually continued Enoxaparin 110 
administration for one month after surgery. 111 
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 112 
We considered as ‘symptomatic’ any patient who presented with pelvic symptoms such as 113 
pelvic fullness, fever, or lower abdominal pain, even if slight, with ultrasound/CT/MRI 114 
feedback showing a lymphocele, according to Kim’s criteria7. 115 
Patients who developed DVT complained of pain, swelling, or discoloration of the affected 116 
extremity; diagnosis was confirmed with doppler/compression ultrasonography. 117 
 118 
Statistical analysis was performed with application of Fisher’s, Mann-Whitney and 119 
Pearson’s Chi-Square Tests. 120 
 121 
 122 
Results 123 
The demographic and clinical characteristics of patients in both groups were comparable, 124 
as was lymph nodes status (p>0.05). There were statistically significant differences in the 125 
pathological staging of cancers (p<0.05), and the median number of lymph nodes removed 126 
(5 vs 10 in standard and P.L.E.A.T. groups, respectively; p<0.00001) [see Table #1]. 127 
The cases of extended PLND (25 vs 35, in standard and P.L.E.A.T. groups, respectively) 128 
were not statistically different (p=0.064). In the 195 PLNDs without P.L.E.A.T. 129 
reconstruction, we found symptomatic lymphocele (Grade ≥3, according to the Clavien 130 
Dindo Classification3) in 8 cases (4.1%) distributed homogeneously (and not grouped in 131 
the first cases). Only one P.L.E.A.T. patient complained of symptoms due to a bilateral 132 
lymphocele, which required percutaneous drainage (p=0.039). Specific data concerning 133 
these patients and the management of complications are shown in Table #2. No patient 134 
reported either complications related to the procedure or any kind of abdominal/pelvic 135 
discomfort. 136 
 137 
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 138 
Comment 139 
The problem of preventing lymphocele after PLND remains an interesting challenge, 140 
particularly in cases of extended PLND. Various solutions have been proposed to limit the 141 
risk, such as the use of new energy sources, or collagen patches coated with human 142 
coagulation factors which provide rapid and reliable hemostasis by creating a robust fibrin 143 
clot adhering to the tissue surface8,9.  144 
 145 
Considering exclusively surgical techniques, a ‘peritoneal fenestration’ is proposed to 146 
prevent the above-mentioned complications: this concept has been extensively studied to 147 
prevent lymphocele development in renal transplantation and a recent review confirmed its 148 
effectiveness10. 149 
In fact, during open radical prostatectomy or extraperitoneal RARP, the occurrence of 150 
lymphocele is significantly lower with fenestration, and the formation of symptomatic 151 
lymphocele requiring surgical intervention was de facto eliminated, without an increase in 152 
postoperative morbidity, as documented by Stolzenburg et al.11. 153 
  154 
Nevertheless, although transperitoneal PLND, as opposed to traditional open or 155 
extraperitoneal approaches, has shown a lower incidence of lymphocele, it still remains 156 
significant12: it may be due to spontaneous ‘re-approximation’ of the edges of the 157 
peritoneum, incised laterally to the medial obliterate ligaments. In many cases, after 158 
release of the pneumoperitoneum after a RARP with PLND, even though the bladder is left 159 
‘dropped’, perivesical fat adheres to the PLND bed, creating a closed space in which 160 
lymphatic fluid accumulates. As reported by Lebeis et al., the bladder often forms the 161 
medial wall of the lymphocele cavity13. 162 
Page 6 of 14
7 
In addiction, when the peritoneum is ‘re-approximated’, the final result is similar to an 163 
extraperitoneal open/laparoscopic radical prostatectomy. 164 
Some authors have proposed the insertion of a peritoneal flap, created by dropping the 165 
bladder from the abdominal wall and fixing it to the lateral aspect of the bladder, at the end 166 
of the procedure: the ‘window’ prevents scarring to the bladder over the PLND area, 167 
allowing lymphatic fluid to drain into the peritoneal cavity and thus be reabsorbed13. As 168 
reported by the authors, this peritonealization of the lateral aspect of the bladder with a. 169 
interposed flap is effective in preventing post-operative lymphoceles. However, this 170 
technique fixes the bladder inferiorly. 171 
As previously reported14, during RARP we usually perform the CoRPUS reconfiguration, in 172 
which, after the creation of a complete support for the urethra, we put a final stitch from the 173 
anterior wall of the bladder to the pubis allowing the bladder, bladder neck and/or posterior 174 
urethra axis to be properly aligned. With this technique, the solution proposed by Lebeis et 175 
al. is not feasible. 176 
 177 
It was from these considerations that we devised and applied the P.L.E.A.T. surgical 178 
technique. The unique nature of this strategy is that the two lateral ‘openings’ do not 179 
collapse when the pneumoperitoneum is removed, because pleating the bladder (into a 180 
more natural position) means that we pull the peritoneum medially, thereby avoiding any 181 
possible spontaneous re-approximation.  182 
The results demonstrated the significant protective effect of this technique in preventing 183 
symptomatic lymphocele, compared with the widespread standard approach, although the 184 
number of lymph nodes removed in the P.L.E.A.T. group was significantly higher 185 
(p<0.00001). 186 
The strengths of this study are: 1. the surgical technique for both limited and extended 187 
PLND was standardized (with only one Hem-o-lock® clip distal to Cloquet’s node and bi-188 
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polar coagulation); 2. In view of the incidence of symptomatic lymphocele reported in the 189 
literature, the number of patients enrolled was adequate (powered statistical analysis); 3. 190 
the technique is simple and easy-to-perform (2-3 min) and is thus easily replicable; 4. the 191 
absence of complications due to the technique allows us to conclude that it is safe. 192 
The limitations of this study are: 1. all the procedures were performed by the same skilled 193 
robotic surgeon: although this avoided any bias due to the differing proficiency and/or 194 
technique of several surgeons, we realize that it may represent a limitation. In effect, it was 195 
in order to reduce the impact of the learning curve that we decided not to consider the first 196 
50 cases; 2. this is a non-randomized study, based on analysis of medical records; 3. both 197 
limited and extended PLND were examined in the same analysis, although both 198 
techniques were similarly distributed in the two groups, nullifying any bias (25 vs 35 199 
extended PLNDs in the standard and P.L.E.A.T. groups, respectively; p>0.05). Although 200 
not significantly higher, the number of extended PLNDs performed in the second ‘era’ far 201 
from being a demonstration of an improvement in technique, only demonstrates an 202 
increase in the number of indications of more clinically extended neoplasms, as confirmed 203 
by the different percentage of pT2/pT3 in the two groups.  Considering that both the 204 
number of lymph nodes removed and the type of cancer represent well-documented risk 205 
factors for symptomatic lymphoceles, this distribution of cases reinforces the protective 206 
role of the P.L.E.A.T. technique. 207 
 208 
 209 
Conclusions 210 
Our preliminary analysis confirms that the P.L.E.A.T. technique is a fast, economic, easy-211 
to-perform and safe method for reducing the risk of symptomatic lymphocele after 212 
transperitoneal robotic PLND. Randomized clinical trials (preferably multi-institutional) are 213 
Page 8 of 14
9 
needed to confirm the efficacy of P.L.E.A.T., maching other recently reported studies 214 
comparing differing techniques for lymphoceles.  215 
  216 
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Legends: 260 
 261 
 262 
Figure #1: (A) Drawing and (B) Intraoperative photo showing bladder peritoneum ‘pleated’ 263 
along midline, leaving two lateral openings, according to the P.L.E.A.T. technique. 264 
 265 
 266 
 267 
  268 
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Table 1. Comparison of patient characteristics in ‘standard’ Group and P.L.E.A.T. Group. 269 
 Group 1 
(standard) 
Group 2 
(P.L.E.A.T.) 
p 
Parameter    
Number of Patients 195 176  
Pathological Staging (%)   0.03* 
pT0 10 (5.1) 1 (0.6)  
pT2(a-b-c) 110 (56.4) 98 (55.7)  
pT3(a-b)/pT4 75 (38.5) 77 (43.7)  
Lymph Nodes Removed    
Median (IR) 5 (0-11) 10 (6.5-15) <0.00001§ 
Positive Nodes (%) 5 (2.6) 11 (6.25) 0.12# 
Extended PLNDs (%) 25 (12.8) 35 (19.9) 0.068* 
Symptomatic Lymphocele 
(%) 
8 (4.1) 1 (0.6) 0.038# 
Symptomatic Lymphocele in 
Extended PLNDs (%) 
1/25 (4) 1/35 (2.9) n.s. 
Follow-up days  
(median, IQR) 
1951 
(1678-2192) 
731.5 
(508-1033) 
 
   *Chi-Square 
§ Mann-Whitney test 
#Fisher’s test 
 270 
  271 
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Table 2. Patients with symptomatic lymphocele 272 
Case # Technique Symptoms Postop Day # Management Successful 
2 no PLEAT fever, DVT 36 PC Drainage yes 
18 no PLEAT pain 45 PC Drainage yes 
82 no PLEAT fever 11 PC Drainage yes 
91 no PLEAT fever, LUTS 38 PC Drainage yes 
98 no PLEAT fever 145 Antibiotics yes 
120 no PLEAT fever, gain 26 PC Drainage yes 
177 no PLEAT fever, DVT 32 PC Drainage yes 
182 no PLEAT DVT 25 PC Drainage yes 
367 PLEAT DVT 26 PC Drainage yes 
DVT: Deep Venous Thrombosis; LUTS: Low Urinary Tract Symptoms; PC: Percutaneous 273 
 274 
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